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Dear Editor, 
We read with keen interest the recently published pa-
per entitled “Ribavirin impairs salivary gland function 
during combination treatment with pegylated interfer-
on alfa-2a in hepatitis C patients” by Aghemo et al(1) in 
your esteemed journal. The study described the eﬀect of 
ribavirin plus interferon therapy (combination therapy) 
on salivary gland function. However, we think we must 
put pen to paper with respect to draw the attention of 
your respectful readers to possible misinterpretation of 
the data that has been presented. 
Even at the beginning of the third millennium, hepati-
tis C virus (HCV) infection remains a major global public 
health problem, and to date, combination therapy seems 
to be the most eﬀective treatment option. Nonetheless, 
this treatment might result in some side eﬀects such 
as lichen planus, skin rash, psychological disturbances, 
poor appetite, anemia, and leucopenia (2).
Derived results of the study by Aghemo et al might be 
aﬀected by some confounding factors. First, although 
the authors had mentioned that a limitation of their 
study was using patients who had hepatitis B virus (HBV) 
infection as the control subjects, it cannot iron out all 
the attributed results of choosing an unsuitable control 
group. Previous studies have shown that HCV infection in 
the epithelial cells of the salivary glands is a factor associ-
ated with the development of sialadenitis and Sjogren’s 
syndrome (3). However, to our knowledge, no previous 
study has shown such a conclusive correlation with HBV 
infection. Because of the observed inconsistencies in 
the ﬁndings of these studies, it does not seem appropri-
ate to conclude that the use of drugs is the sole cause of 
salivary gland malfunction. In addition, it is unclear that 
why the authors used such a small control group; the use 
of a small sample size raises questions regarding the reli-
ability of the rate of side eﬀects expressed by the patients 
in this group.
An advantage of their study was that they used stimu-
lated saliva for evaluating sialadenitis. Previous studies 
have conﬁrmed that stimulated whole saliva is especially 926  Eﬀect of Ribavirin Therapy on Salivary Gland Function Mahboobi N et al.
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useful in measuring salivary gland function in patients 
with common autoimmune disorders. The main advan-
tage of gustatory stimulation is reduction in the variabil-
ity of salivary ﬂow rates among study subjects (4). Sever-
al studies have been conducted on the role of oral ﬂuids 
(namely saliva and gingival crevicular ﬂuid) in viral hep-
atitis. However, no conclusive results have been obtained 
on the role of oral ﬂuids in the transmission or diagnosis 
of viral hepatitis, its progress, or treatment monitoring. 
Further studies are required to assess the variations 
in the levels of oral ﬂuid secretion in patients with viral 
hepatitis. If such changes can be proven, it might help 
identify why the rate of dental caries is signiﬁcantly 
higher in patients with HCV infection than in the general 
population (5).
We suggest that randomized controlled trials and ex-
perimental observations, including salivary gland func-
tion monitoring before and after treatment, to be con-
ducted in HCV-infected patients. Evaluating the presence 
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